MX394588B - Composición farmacéutica. - Google Patents

Composición farmacéutica.

Info

Publication number
MX394588B
MX394588B MX2018006903A MX2018006903A MX394588B MX 394588 B MX394588 B MX 394588B MX 2018006903 A MX2018006903 A MX 2018006903A MX 2018006903 A MX2018006903 A MX 2018006903A MX 394588 B MX394588 B MX 394588B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
compositions
agent
compositions containing
cyanonaphthalen
Prior art date
Application number
MX2018006903A
Other languages
English (en)
Other versions
MX2018006903A (es
Inventor
Christer Tannergren
Corswant Christian Von
Colin Rowlings
Gerry Burke
Joanne Reiland Wakeman
Johan Hjärtstam
Sha Liu
Original Assignee
Ardea Biosciences Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57517882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394588(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc, Astrazeneca Ab filed Critical Ardea Biosciences Inc
Publication of MX2018006903A publication Critical patent/MX2018006903A/es
Publication of MX394588B publication Critical patent/MX394588B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que contienen ácido 2-((3-(4-cianonaftalen-1-iI)piridin-4-il)tio)-2-metilpropanoico o una sal farmacéuticamente aceptable (en lo sucesivo en el presente documento denominado "Agente "), más particularmente a composiciones administrables por vía oral que contienen el Agente; al uso de dichas composiciones como un medicamento; y a procesos para la preparación de dichas composiciones.
MX2018006903A 2015-12-08 2016-12-07 Composición farmacéutica. MX394588B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264792P 2015-12-08 2015-12-08
PCT/EP2016/080111 WO2017097845A1 (en) 2015-12-08 2016-12-07 Pharmaceutical composition comprising a potent inhibitor of urat1

Publications (2)

Publication Number Publication Date
MX2018006903A MX2018006903A (es) 2018-11-09
MX394588B true MX394588B (es) 2025-03-24

Family

ID=57517882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006903A MX394588B (es) 2015-12-08 2016-12-07 Composición farmacéutica.

Country Status (20)

Country Link
US (3) US20180360761A1 (es)
EP (1) EP3386485A1 (es)
JP (2) JP6976946B2 (es)
KR (1) KR20180082613A (es)
CN (1) CN108289848A (es)
AU (1) AU2016368622B2 (es)
BR (1) BR112018011376A2 (es)
CA (1) CA3006167A1 (es)
CL (1) CL2018001510A1 (es)
CO (1) CO2018005842A2 (es)
EA (1) EA038828B9 (es)
HK (2) HK1256256A1 (es)
IL (1) IL259844B (es)
MA (1) MA43402A (es)
MX (1) MX394588B (es)
PE (1) PE20181521A1 (es)
PH (1) PH12018501236A1 (es)
SG (1) SG11201804100UA (es)
WO (1) WO2017097845A1 (es)
ZA (1) ZA201804519B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010495A2 (pt) * 2011-11-03 2017-04-25 Ardea Biosciences Inc composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
SG11202103078WA (en) * 2018-10-01 2021-04-29 Astrazeneca Ab Compositions for reducing serum uric acid
CN112057429B (zh) * 2019-06-11 2023-04-07 上海京新生物医药有限公司 雷西纳德控释药物组合物
KR20220035156A (ko) * 2019-07-16 2022-03-21 아스트라제네카 아베 베리누라드를 포함하는 과량 방출 저항성 약제학적 조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
WO2022162021A1 (en) 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
WO2023039850A1 (zh) * 2021-09-17 2023-03-23 海创药业股份有限公司 一种喹啉类化合物缓释片及其制备方法
JP7515533B2 (ja) * 2022-04-28 2024-07-12 沢井製薬株式会社 デスロラタジン含有フィルムコーティング錠剤
EP4601742A2 (en) * 2022-10-04 2025-08-20 Engrail Therapeutics, Inc. Gaba receptor modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물
US20070048371A1 (en) * 2005-07-28 2007-03-01 Shojaei Amir H Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
HUE038265T2 (hu) * 2010-06-15 2018-10-29 Ardea Biosciences Inc Köszvény és hiperurikémia kezelése
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112014010495A2 (pt) * 2011-11-03 2017-04-25 Ardea Biosciences Inc composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo

Also Published As

Publication number Publication date
AU2016368622A1 (en) 2018-06-07
PE20181521A1 (es) 2018-09-24
CO2018005842A2 (es) 2018-07-10
US20230011269A1 (en) 2023-01-12
US20210113472A1 (en) 2021-04-22
AU2016368622B2 (en) 2022-09-08
CN108289848A (zh) 2018-07-17
EA201891267A1 (ru) 2019-01-31
IL259844A (en) 2018-07-31
JP2022033758A (ja) 2022-03-02
CA3006167A1 (en) 2017-06-15
KR20180082613A (ko) 2018-07-18
CL2018001510A1 (es) 2018-09-21
JP6976946B2 (ja) 2021-12-08
HK1256256A1 (zh) 2019-09-20
US20180360761A1 (en) 2018-12-20
IL259844B (en) 2022-04-01
EP3386485A1 (en) 2018-10-17
ZA201804519B (en) 2022-04-28
BR112018011376A2 (pt) 2018-12-04
EA038828B9 (ru) 2021-12-03
JP2019501895A (ja) 2019-01-24
PH12018501236A1 (en) 2019-02-18
WO2017097845A1 (en) 2017-06-15
HK1253034A1 (zh) 2019-06-06
MA43402A (fr) 2018-10-17
MX2018006903A (es) 2018-11-09
SG11201804100UA (en) 2018-06-28
EA038828B1 (ru) 2021-10-26

Similar Documents

Publication Publication Date Title
MX394588B (es) Composición farmacéutica.
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
JO3256B1 (ar) صياغات من مركبات عضوية
EA201692298A1 (ru) Производные карбоксамидов
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
HUE071451T2 (hu) Vegyület, gyógyászatilag elfogadható sója vagy optikai izomere, eljárás elõállítására és hatóanyagként azt tartalmazó, vírusos betegség megelõzésére vagy kezelésére szolgáló gyógyászati készítmény
PH12016502247A1 (en) Carboxamide derivatives
EA201990656A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MX2017000580A (es) Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo.